Trastuzumab Emtansine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Trastuzumab Emtansine
Trastuzumab Emtansine: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidate indications for Trastuzumab Emtansine. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The four known uses listed below belong to the same disease category as an approved indication.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 4 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| normal breast-like subtype of breast carcinoma | breast cancer |
| progesterone-receptor positive breast cancer | breast cancer |
| progesterone-receptor negative breast cancer | breast cancer |
| breast tumor luminal A or B | breast cancer |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10281D | Kadcyla | Powder for I.V. infusion 100 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate (targeted therapy delivering a cytotoxic microtubule inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI. Haematological parameters and liver function are typically monitored for this class. |
| Handling Protection | Handle according to local cytotoxic drug handling requirements |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications. No label-derived data were available for this report.
Drug Interactions: The interaction screen returned 100 potential interactions. The main examples are listed below.
- Major: acetylsalicylic acid, deferasirox, abciximab, apixaban, argatroban, betrixaban, bivalirudin, cangrelor, caplacizumab and cilostazol. Most are antithrombotic or antiplatelet agents, so the bleeding risk should be considered.
- Moderate: clarithromycin, metronidazole, tinidazole, naltrexone, rosuvastatin, simvastatin, cobicistat, fenfluramine, dexfenfluramine and sibutramine.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.